Bard transvaginal mesh lawsuits
The Bard transvaginal mesh lawsuits are progressing in a federal court in West Virginia. The law firm representing plaintiffs has changed the dates for its monthly status conferences. Previously, the judge had scheduled a Nov. 7 meeting, but now he has ordered a Dec. 5 meeting instead.
The plaintiffs claim that Bard failed to warn them of the risks associated with its transvaginal mesh products. The company is accused of putting profits before the health and safety of its patients. For example, a woman from Mississippi sued Bard after receiving a mesh implant. Her lawyers claim that her implant caused organ damage and made sexual intercourse painful.
Although Bard settled some of these lawsuits, there are still thousands of other women who are pursuing legal claims. The company has admitted to hiding some flaws from the public. In one case, a jury found that Bard had concealed the risks of transvaginal mesh by not disclosing them. The plaintiff, Donna Cisson, received $250,000 in compensatory damages and over $1.75 million in punitive damages.
Dangers of C. R. Bard transvaginal mesh implants
The lawsuits stemmed from the failure to warn doctors and consumers of the risks associated with transvaginal mesh implants. A settlement was reached with C.R. Bard, which is part of Becton Dickinson and Company. The medical device manufacturer has agreed to pay $60 million to the states, including $2,160,246 for New York state. The company will also be subject to certain injunctive conditions if it re-enters the transvaginal mesh market. These terms require that the company disclose the risks associated with transvaginal mesh products in its marketing materials and training materials. In addition, the company will have to disclose any sponsorship of clinical studies.
After the FDA issued its order in July 2012, the manufacturers and distributors of transvaginal mesh recalled their products. The agency said the mesh products were not safer than other surgical treatments, and could increase the risk of serious adverse events. The FDA’s ruling reclassified the mesh as a class III device, which means that the device poses a high risk.
Manufacturer’s failure to warn patients of serious complications
In 2009, Mary McGinnis underwent surgery with pelvic mesh to treat stress urinary incontinence and bladder support. Shortly after the procedure, she started experiencing chronic pain and other complications. She ultimately underwent several surgeries to correct the problem.
The FDA warned patients about serious complications of the Bard Avaulta mesh, but the manufacturer did not adequately warn patients about the risks. The mesh is difficult to remove and may result in severe bleeding and permanent disfigurement. Moreover, the mesh could be infected or eroded and cause life-threatening complications.
In 2011, the FDA issued a Public Health Notification and Additional Patient Information for surgical Mesh. The warnings stated that the risks associated with the mesh procedure were not rare and that there was no proof that mesh surgery alleviated symptoms. In July 2012, C.R. Bard recalled its Avaulta Plus transvaginal mesh product, citing these risks.
Settlement reached in Bard Avaulta lawsuit
A settlement reached in the Bard Avaulta lawsuit will prevent a multimillion dollar verdict for plaintiff Donna Cisson. She sued Bard for negligence after the company failed to test its surgical mesh in humans. The settlement covers a total of $250,000 in compensatory damages, plus $1.75 million in punitive damages.
The settlement was reached after Bard lost the first trial in the Avaulta lawsuit. Donna Cisson suffered painful side effects after the device was implanted in her cervix. She had several follow-up surgeries to remove the implant. Her lawyers claimed that Bard put profits ahead of her health and safety.
A multidistrict litigation was created to handle these cases. This allowed early trial dates to evaluate juries’ response to evidence and testimony. The first trial date in the Bard Avaulta lawsuit, scheduled for November 2013, was delayed to January 2014 and then to April 2014. However, due to a family illness, an important expert witness for the plaintiff couldn’t attend. In addition, the Jones trial was canceled because of the settlement reached in the Bard Avaulta lawsuit.
Class action lawsuits filed against Bard
The company that manufactures the Avaulta mesh is facing a wave of lawsuits filed by women who were implanted with the mesh. The plaintiffs allege that Bard failed to adequately warn patients of the risks associated with the device, resulting in the mesh becoming defective and leading to infections and other complications. More than 8,000 personal injury lawsuits are pending against the company.
The Avaulta mesh implant was designed to support pelvic organs that have fallen out of place after childbirth or surgery. This causes pressure on the vagina and can cause pain, discomfort, and urinary incontinence. Patients who have undergone the procedure may qualify for financial compensation.